ABSTRACT Gallium-67 (67Ga) scanning was assessed for its usefulness in the evaluation and follow-up of 54 patients with sarcoidosis, both treated and untreated. Scans were repeated in 23 subjects. Serum levels of angiotensin-converting enzyme (ACE) were determined concurrently in all 54 patients and bronchoalveolar lavage was performed in 29 patients. 
Sarcoidosis, a systemic granulomatous disease of unknown cause may involve such a variety of sites as to require multiple methods of investigation. The course of the disease is unpredictable. Customary investigative approaches give a relatively poor idea of the spread and activity of the granulomatous process. Recently, serum angiotensin-converting enzyme (ACE)1 and the lymphocyte count in bronchoalveolar lavage fluid2 have been proposed as markers of disease activity. The object of the present study was to assess the usefulness of 67Ga uptake as another possible marker. Gallium-67 concentrates in inflammatory tissue34 through an imperfectly understood mechanism. It is commonly used to identify occult postoperative abscesses. Several investigators5-15 have reported particularly intense concentration of gallium in sarcoid granulomas and, in 19 In a previous study a control population had shown the upper limit of normal to be 33 U/ml. '9 In 29 patients bronchoalveola'r lavage was performed simultaneously with the above studies. Saline was pumped into the lungs through a fibreoptic bronchoscope and gently recovered in 30 ml pulses to a total of 300 ml. The lavage fluid was analysed by the method of Reynolds,20 the alveolar lymphocyte count being expressed as number of cells/l00 ml fluid. In 18 patients the T-lymphocyte population was quantified by anti-T-cell cytotoxicity.
Results

CONTROLS
Scanning data obtained from control subjects have been detailed in a previous report.16 They were with observations described by other investigators:21 22 72 hr after injection, activity over the liver was pronounced in all cases, with diffuse uptake in the skeleton as a whole but no uptake in mediastinum, lungs or salivary glands (fig 1) . Grade 1 uptake was noted in the eyes and nose, and breast uptake in 45 % of the women examined.
PATIENTS
Of the 70 scans performed in the sarcoid patients seven were normal: of these seven, three concerned group B patients (in regression), two group C patients (receiving treatment) and two group A (chronic sarcoidosis of undetermined activity). In the remaining 63 patients sites of abnormal 67Ga uptake were many and varied (figs 2, 3) including mediastinum, lung, salivary glands, eyes, nose, spleen, and less frequently, lymph nodes, bone, and skin ( Gallium-67 images of thoracic uptake were not in keeping with radiographic appearances in a number 4Beaumont, Herry, Sapenie, Bourguet, Larzul, seen for all aspects studied: clinical and radiographic appearances, serum ACE, and f67Ga scans. In 13 cases the findings were discordant: two group B patients, for example, showed recovery of normal gallium scans before recovery of normal radiographic appearances and five group C patients on corticosteroids showed persistent 67Ga uptake after serum ACE levels had returned to normal. In certain cases the usefulness of 67Ga scanning was particularly evident. In one patient not receiving treatment, for example, the onset of intense focal uptake of radiotracer in the spleen coincided with a sudden rise in ACE (fig 7) . In another patient who had been receiving therapy for three years and had a normal serum ACE level, an optimistic prognosis was offset by images of 67Ga uptake in the spleen, which, it turned out, heralded an otherwise unpredicted abrupt relapse on stopping therapy. This was followed by spontaneous regression, although uptake persisted in the spleen.
Discussion
Accurate evaluation of gallium scans in sarcoid patients can only be done if intensity of uptake for each site is compared with that in corresponding sites in control subjects. Thus, the consistent absence of pulmonary or mediastinal uptake in thoracic scans of controls lends considerable significance to the finding of such an uptake pattern in a patient with sarcoidosis-a disease almost always involving these sites.25 Uptake in the breast was seen in 45 % of the female patients of the series, a rate higher than that reported by other workers. In our study, breast images were readily distinguished from patterns of pulmonary uptake, especially in posterior and lateral views. There have been a few reports of normal salivary gland uptake.13 21 In the control subjects of the present study no Quantifying radiogallium uptake is a complex problem. The method adopted by other investigators and used in the present study is open to two major criticisms: it fails to evaluate the extent of uptake and does not clearly distinguish small focal areas of uptake from a diffuse uptake pattern of the same intensity, a shortcoming particularly pertinent to lung imaging. A pulmonary uptake index taking into account extent of uptake has been proposed28 which should make for more accurate scan assessment, although only for lung images. Another objection to the method used in most studies is that grading was based on hepatic uptake in patients with a disease frequently affecting the liver. We are currently developing a more accurate method of quantification based on the actual amount of tracer administered and the quantity accumulated in each site, whatever the intensity of hepatic uptake.
Gallium-67 scanning is not specific enough for formulation of a definite diagnosis of sarcoidosis. It can, though, offer supportive evidence for a presumptive diagnosis based on clinical and radiographic evidence especially if the radiogallium uptake pattern reflects the multisystem nature of the disease. Nosal et al15 consider the association of pulmonary uptake with elevated serum ACE levels to be 99 % specific for sarcoidosis. Pulmonary uptake ofgallium,29 however, and sometimes elevated ACE levels30 have both been reported in silicosis patients. We share the view of De Remee et al3 that the results of these techniques must be confirmed by histopathological examination before definitive diagnosis can be established.
Gallium-67 scans sometimes merely confirm known sites of disease involvement. The advantage, though, is that with a single non-invasive investigation one has an overall view of the disease pattern, sometimes obviating the need for additional explorations, such as mediastinal tomography and scans of the salivary glands or spleen. In addition, hitherto unsuspected lesions are often detected by gallium scans. Instances of mediastinal adenopathy for example, invisible on radiographs but disclosed by gallium scintigraphy, were seen in the present study and have been described by others.7 10 In our experience, scanning evidence of subclinical salivary gland or splenic involvement is also common.
Finally, in three patients in the present study 67Ga scanning was more sensitive than radiography in detecting pulmonary lesions. Some lesions, however, notably of the skin or heart, were too small to show up on gallium scan. Others, as in the liver, were hidden by normal intense uptake.
With thoracic sites of involvement 67Ga scans enable granulomatous lesions, which accumulate tracer, to be distinguished from fibrotic lesions, which do not. In the present series 67Ga scans revealed fibrotic residua in Although 67Ga scintigraphy is an innocuous, simple method of investigation and is thus suitable for outpatient use, two limiting factors must be considered: cost and radiation dose delivered to the patient. Estimated whole-body dose is 260 mrad/mCi, equivalent to an average of 600 mrad per examination; the dose to the gonads is of the same order. Although low,36 37 this dose is not a negligible consideration in young patients.
In conclusion, the findings of the present study highlight certain problem areas where 67Ga scanning is useful in the investigation of sarcoidosis. These are, firstly, diffuse chronic pulmonary involvement, where granulomatous lesions can be distinguished from fibrosis; secondly, cases where several organsystems are involved and where certain sites may be missed; and thirdly, sarcoid patients on treatment, in whom 67Ga scans may offer evidence of persistent disease activity and thus a solid basis for planning the dosage and duration of continued treatment. Whether or not routine use of 67Ga scintigraphy should be envisaged for the diagnosis, staging and follow-up of all sarcoid patients is a question that requires further study. One factor to be considered is the abandonment of classical investigative methods, notably repeat tomography, that would result from such a decision.
